Your Thyroid Problem Is Actually A Conversion Problem

Your thyroid probably makes enough hormone. The problem is what happens to it after it leaves the gland.

To understand why that matters, you need the full chain first. Your pituitary gland releases something called TSH, which stands for thyroid stimulating hormone and functions essentially as a signal telling your thyroid how hard to work. Your thyroid responds by producing a hormone called T4, which is the storage form, the raw material your body ships out into circulation without much biological effect on its own. Then peripheral tissues, your liver, your kidneys, your skeletal muscle, take that T4 and convert it into T3, which is the active form that actually enters your cells and changes how they function. T3 is the hormone that sets your metabolic rate, your energy, your mood, your body temperature, and your ability to lose fat.

That conversion step is where most thyroid problems actually live.

The standard blood test your doctor orders measures TSH and stops there. If TSH is in range, the assumption is that the whole system is working. But TSH only tells you what the pituitary is signaling. It says nothing about whether the conversion from T4 to T3 is actually happening downstream, and it says nothing about how much active hormone is reaching your cells. A 2011 study published in PLoS ONE followed patients on levothyroxine, which is the synthetic T4 most hypothyroid people are prescribed, and found that more than 20 percent of them had abnormal free T3 or free T4 levels despite completely normal TSH readings. One in five patients on medication, labs looking fine on paper, but the active hormone still off.

That gap exists because the conversion is handled peripherally, not by the thyroid itself.

Between 70 and 90 percent of your active T3 is made outside the thyroid gland through a process called deiodination, which means removing an iodine atom from T4 to produce T3. The enzymes that do this are called deiodinases, and they live primarily in the liver and kidneys using something called D1, and in skeletal muscle using something called D2. The liver and kidneys handle the bulk of systemic conversion. The muscle tissue handles local conversion for its own cells, which becomes important in a moment.

This is why muscle mass matters for thyroid function in a way most people never connect. More muscle tissue means more sites where your body can convert T4 into usable T3. It also means more tissue that depends on T3 to function properly, which creates a feedback signal for more conversion to occur. When someone loses significant muscle mass, whether through illness, sedentary lifestyle, or chronic dieting, they are reducing the very tissue that drives a large portion of their thyroid hormone activation.

Exercising that muscle tissue does more than just build it. A 2025 cross sectional study found that recreational exercise in people with Hashimoto's thyroiditis, which is the autoimmune form of hypothyroidism, was associated with significantly reduced inflammatory markers including TPO antibodies, which are the antibodies attacking the thyroid itself. Exercise is not just building the conversion machinery. It is reducing the immune attack on the gland producing the raw material.

Now look at what breaks conversion before any of that can happen.

The deiodinase enzymes require selenium to function. Selenium is the cofactor that makes deiodination work, and most people eating a processed diet or restricting food intake are not consistently getting enough. Low protein intake compounds this because the enzymes themselves are proteins, and because low protein signals the body into a catabolic state that suppresses metabolic activity broadly. Then there is cortisol.

Chronic stress drives high cortisol, and high cortisol actively suppresses T4 to T3 conversion while simultaneously increasing production of something called reverse T3, which is a mirror image of T3 that binds to T3 receptors without activating them. Reverse T3 functions like a key that fits the lock but does not open the door, and high levels block active T3 from doing its job even when conversion is technically occurring. This is why people in chronically stressful periods can develop every symptom of hypothyroidism while their TSH looks completely normal. The raw material is there. The conversion is impaired. The active hormone is being blocked. And the standard test sees nothing unusual.

Fixing this is not a single lever. It is several levers pulled at the same time.

Protein intake is the place to start because it does multiple things simultaneously. A 2025 case report documented a patient with Hashimoto's thyroiditis who followed a structured high protein protocol and saw her thyroid antibodies normalize and her symptoms resolve over the following months. The protein provides the substrate for enzyme production, supports muscle tissue that drives peripheral conversion, and takes the body out of the catabolic signaling state that suppresses the whole pathway. The target is not a modest protein intake. It is treating protein the way you would treat a medication, consistent timing, consistent amounts, non negotiable.

Training with resistance is the second lever because it builds the conversion tissue directly, reduces the autoimmune inflammation that degrades the gland, and improves the cellular sensitivity to T3 that allows the hormone to do its job once it gets there.

Sleep matters here in a way that does not get enough attention. The majority of growth hormone and IGF-1 are released during deep sleep, and thyroid hormone status directly regulates IGF-1 levels. Poor sleep keeps cortisol elevated, which keeps reverse T3 elevated, which keeps the whole system suppressed. You cannot out supplement disrupted sleep.

If lifestyle correction does not resolve the symptoms, the next clinical move is asking about T3 directly, not more T4. A 2022 trial published in Frontiers in Endocrinology found that adding liothyronine, which is synthetic T3, to levothyroxine therapy significantly improved quality of life scores in women with residual hypothyroid symptoms who had normalized TSH. The conversion problem was bypassed entirely by supplying the active hormone the body was failing to produce on its own.

Most people on thyroid medication never get offered this because the current guidelines recommend monitoring TSH without routinely testing free T3, which means the gap between what the test shows and what the patient feels never gets investigated.

The test that medicine standardized around in the 1970s was built to screen for gross thyroid failure. It was not built to assess whether a person with enough T4 is actually converting it, using it, or being blocked from using it. A normal TSH alongside persistent fatigue, cold intolerance, weight resistance, and low mood is not a mystery. It is a conversion problem waiting to be diagnosed.

---

References

1. Gullo D, Latina A, Frasca F, Le Moli R, Pellegriti G, Vigneri R. (2011). Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients. PLoS ONE 6(8):e22552. PMC3148220.
2. Cited for: the >20% of patients with abnormal FT3 or FT4 despite normal TSH on levothyroxine.
3. Limbaugh SL, Ennessy LA, Davis KS, Allen VT. (2025). Nutrition Based, High Protein Adjunct Therapy for Hashimoto's Thyroiditis: A Case Report. Cureus 17(9):e91597. PMC12495900.
4. Cited for: protein protocol resolving Hashimoto's symptoms.
5. Vuletić M, Žnidar V, Barić Žižić A, et al. (2025). Recreational Exercise and Inflammatory Patterns in Hashimoto's Thyroiditis: Observations from a Cross Sectional Study. Biomolecules 15(11):1510. PMC12650045.
6. Cited for: exercise reducing inflammatory markers in Hashimoto's patients.
7. Bjerkreim BA, Hammerstad SS, Gulseth HL, et al. (2022). Effect of Liothyronine Treatment on Quality of Life in Female Hypothyroid Patients With Residual Symptoms on Levothyroxine Therapy. Frontiers in Endocrinology 13:816566. PMC8902821.
8. Cited for: clinical evidence that adding T3 improves quality of life in patients with residual symptoms.
9. Lindner HH. (2025). Clinical thyroidology: beyond the 1970s' TSH T4 Paradigm. Frontiers in Endocrinology 16:1529791. PMC12234311.
10. Cited for: critique of the TSH only diagnostic model. Note: single author opinion piece.
11. European Thyroid Journal. Role of hepatic deiodinases in thyroid hormone homeostasis. PMC10160546.
12. Cited for: D1 distribution in liver and kidney, D2 distribution in skeletal muscle.
13. ScienceDirect Topics. Thyroxine Deiodinase.
14. Cited for: the 70-90 percent peripheral conversion figure.
15. Pituitary Foundation. Hormone Replacement Medication Interactions.
16. Cited for: thyroid hormone status affecting IGF-1 levels.
17. American Thyroid Association Guidelines on Treatment of Hypothyroidism.
18. Cited for: current guideline recommending TSH for monitoring without routine FT3 or rT3 testing.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness